How does selpercatinib stop RET-positive cancer?
Selpercatinib is a kinase inhibitor that blocks the RET protein, a broken switch that tells cancer cells to grow. By shutting off this switch, the drug starves tumors and lets your immune system catch up. In clinical trials, 64–73% of patients saw their tumors shrink [1][2].
In real-world trials, selpercatinib shrank tumors in 64% of patients with RET-positive lung cancer and 73% of those with medullary thyroid cancer [1][4]. These response rates beat chemotherapy alone by a wide margin. Patients on selpercatinib stayed cancer-free longer—some for 24+ months without their cancer growing back [1].
Inside your body, RET is a protein that acts like a light switch for cancer cell growth. When the RET gene is broken or fused to another gene, the switch gets stuck in the 'on' position. Selpercatinib fits into the RET protein like a key in a lock and turns the switch off, stopping cancer cells from dividing [2].
The trade-off is that selpercatinib also affects healthy cells. About 60% of patients get diarrhea, 45% feel tired, and 35% develop high blood pressure [7]. Most side effects are mild and manageable—your oncologist can lower your dose or add a second medicine to control them. The key is catching side effects early by checking in with your cancer team every 2–4 weeks [8].
Ask your oncologist: 'How often will we check my blood pressure and liver function?' Catching side effects early means you can stay on the dose that works best for your cancer without suffering needlessly.